Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Adamis Pharmaceuticals Corp Signs Agreement To Acquire Dry Powder Inhaler Technology From 3M Co


Tuesday, 6 Aug 2013 09:30am EDT 

Adamis Pharmaceuticals Corp announced that it has entered into an agreement to exclusively license and, with additional payment, fully acquire 3M Co's Taper Dry Powder Inhaler (DPI) technology under development for the treatment of asthma and chronic obstructive pulmonary disease (COPD). As a part of the agreement, Adamis will obtain worldwide rights to use this platform technology in all indications in the dry powder inhalation field. The unique design uses proprietary 3M technology to store active pharmaceutical ingredient (API) on a microstructured carrier tape. 3M will supply the drug delivery tape for the platform to Adamis under a separate supply agreement. 

Company Quote

144.37
-1.34 -0.92%
23 Sep 2014